HALOZYME THERAPEUTICS, INC. (HALO) Latest Company News

Oct 22, 2026, 12:30 UTC
Halozyme announced that it will release its third-quarter 2026 financial and operating results on November 5, 2026, after market close, and host a conference call at 1:30 p.m. PT/4:30 p.m. ET.
Source:
- prnewswire.com
Oct 7, 2026, 16:01 UTC
Halozyme expanded its ENHANZE collaboration and licensing agreement with ARGENX SE to cover eight targets, creating eligibility for additional milestone payments and royalties.
Source:
- zacks.com
Oct 7, 2026, 12:30 UTC
Merck & Co., Inc. found Merck to infringe Halozyme's EP 2,797,622 patent and enjoined MSD AG from manufacturing, marketing, using, importing or stocking Keytruda SC in eight European markets.
Source:
Sep 30, 2026, 20:24 UTC
Halozyme Therapeutics, Inc. appointed James Daly to its Board of Directors effective September 28, 2026, with compensation including cash retainers and restricted stock and stock option awards.
Sep 22, 2026, 20:47 UTC
Halozyme Therapeutics, Inc. entered into capped call transactions with certain initial purchasers or their affiliates and other financial institutions, at a cap price of about $208.39 per share, to reduce potential dilution from the convertible notes.
Sep 22, 2026, 20:47 UTC
Halozyme Therapeutics, Inc. repurchased about $151.7 million principal of its 2027 notes for roughly $217.0 million and about $220.0 million principal of its 2028 notes for roughly $435.5 million.
Sep 22, 2026, 20:47 UTC
Halozyme Therapeutics, Inc. issued $1.5 billion aggregate principal amount of 1.50% Convertible Senior Notes due 2033, with net proceeds of about $1.471 billion.
Sep 16, 2026, 20:30 UTC
Halozyme Therapeutics announced a proposed offering of $1.05 billion aggregate principal amount of convertible senior notes due 2033.
Source:
Sep 11, 2026, 11:58 UTC
Halozyme Therapeutics reported record second-quarter fiscal 2026 revenue of $481 million, up 48% year over year, with non-GAAP diluted EPS of $1.90, and raised its full-year 2026 guidance.
Source:
- fxempire.com
Aug 22, 2026, 07:07 UTC
Allworth Financial LP acquired a new stake in Halozyme Therapeutics, Inc. during the second quarter, buying 37,664 shares valued at approximately $2,948,000.
Source:
- defenseworld.net
Aug 18, 2026, 00:00 UTC
Halozyme Therapeutics appointed Dannielle Appelhans as a director, effective August 14, 2026.
Aug 6, 2026, 22:21 UTC
Halozyme Therapeutics reported Q2 2026 earnings of $2.28 per share, surpassing the Zacks Consensus Estimate of $1.82 per share and up from $1.54 per share a year ago.
Source:
Aug 6, 2026, 07:07 UTC
Amundi acquired additional shares of Halozyme Therapeutics, increasing its stake by 503.5% during the quarter.
Source:
- defenseworld.net
Jul 21, 2026, 15:40 UTC
Halozyme Therapeutics grants Incyte Corporation rights to its ENHANZE drug delivery technology for developing subcutaneous formulations of cancer therapies.
Source:
- zacks.com
Jul 2, 2026, 00:00 UTC
Cortney Caudill will depart as Senior Vice President and Chief Operating Officer of Halozyme Therapeutics, Inc. effective June 30, 2026.

HALO

Halozyme announced that it will release its third-quarter 2026 financial and operating results on November 5, 2026, after market close, and host a conference call at 1:30 p.m. PT/4:30 p.m. ET.

Halozyme expanded its ENHANZE collaboration and licensing agreement with ARGENX SE to cover eight targets, creating eligibility for additional milestone payments and royalties.

Merck & Co., Inc. found Merck to infringe Halozyme's EP 2,797,622 patent and enjoined MSD AG from manufacturing, marketing, using, importing or stocking Keytruda SC in eight European markets.

Halozyme Therapeutics, Inc. appointed James Daly to its Board of Directors effective September 28, 2026, with compensation including cash retainers and restricted stock and stock option awards.

Halozyme Therapeutics, Inc. entered into capped call transactions with certain initial purchasers or their affiliates and other financial institutions, at a cap price of about $208.39 per share, to reduce potential dilution from the convertible notes.

Halozyme Therapeutics, Inc. repurchased about $151.7 million principal of its 2027 notes for roughly $217.0 million and about $220.0 million principal of its 2028 notes for roughly $435.5 million.

Halozyme Therapeutics, Inc. issued $1.5 billion aggregate principal amount of 1.50% Convertible Senior Notes due 2033, with net proceeds of about $1.471 billion.

Halozyme Therapeutics announced a proposed offering of $1.05 billion aggregate principal amount of convertible senior notes due 2033.

Halozyme Therapeutics reported record second-quarter fiscal 2026 revenue of $481 million, up 48% year over year, with non-GAAP diluted EPS of $1.90, and raised its full-year 2026 guidance.

Allworth Financial LP acquired a new stake in Halozyme Therapeutics, Inc. during the second quarter, buying 37,664 shares valued at approximately $2,948,000.

Halozyme Therapeutics appointed Dannielle Appelhans as a director, effective August 14, 2026.

Halozyme Therapeutics reported Q2 2026 earnings of $2.28 per share, surpassing the Zacks Consensus Estimate of $1.82 per share and up from $1.54 per share a year ago.

Amundi acquired additional shares of Halozyme Therapeutics, increasing its stake by 503.5% during the quarter.

Halozyme Therapeutics grants Incyte Corporation rights to its ENHANZE drug delivery technology for developing subcutaneous formulations of cancer therapies.

Cortney Caudill will depart as Senior Vice President and Chief Operating Officer of Halozyme Therapeutics, Inc. effective June 30, 2026.